Viral hepatitis in resource-limited countries and access to antiviral therapies: Current and future challenges

Future Virology

Volumn 8, Issue 4, 2013, Pages 371-380

  Lemoine, Maud ^a   Nayagam, Shevanthi ^b   Thursz, Mark ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

DAA; global health; HBV; HCC; HCV; HIV AIDS; resource limited countries; social justice; treatment

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; ENTECAVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG MARKETING; HEALTH CARE ACCESS; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LOGIC; MIXED INFECTION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SOCIAL JUSTICE; VACCINATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84876119585     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.11     Document Type: Review

References (66)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17, 107-115 (2011).
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin, DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer (2010).
3. Kirk GD, Lesi OA, Mendy M et al. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in west Africa. Hepatology 39(1), 211-219 (2004).
4. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 328, 1797-1801 (1993).
5. Jemal A, Bray F, Forman D et al. Cancer burden in Africa and opportunities for prevention. Cancer 118(18), 4372-4384 (2012).
6. de Martel C, Ferlay J, Franceschi S et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13, 607-615 (2012).
7. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264-1273 (2012).
8. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N. Engl. J. Med. 292, 771-774 (1975).
9. Whittle HC, Bradley AK, McLauchlan K et al. Hepatitis B virus infection in two Gambian villages. Lancet 1, 1203-1206 (1983).
10. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc. Biol. Sci. 253, 197-201 (1993).
11. Goldstein ST, Zhou F, Hadler SC et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34, 1329-1339 (2005).
12. European Association for the Study of the Liver. Clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57, 167-185 (2012).
13. Lin X, Robinson NJ, Thursz M et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol. Hepatol. 20, 833-843 (2005).
14. Yang HI, Yeh SH, Chen PJ et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst. 100, 1134-1143 (2008).
15. El-Serag HB. Hepatocellular carcinoma. N. Engl. J. Med. 365, 1118-1127 (2011).
16. Ocama P, Seremba E. Management of HIV and hepatitis C virus infections in resource-limited settings. Curr. Opin. HIV AIDS 6, 539-545 (2011).
17. Paez Jimenez A, Mohamed MK, Eldin NS et al. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS ONE 4, e7193 (2009).
18. Nelson PK, Mathers BM, Cowie B et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378, 571-583 (2011).
19. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment. Pharmacol. Ther. 32, 344-355 (2010).
20. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co infection in Asia and Africa. Lancet Infect. Dis. 7, 402-409 (2007).
21. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 61 (Suppl. 1), i47-i58 (2012).
22. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 377, 1198-1209 (2011).
23. Salmon-Ceron D, Rosenthal E, Lewden C et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J. Hepatol. 50, 736-745 (2009).
24. Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin. Liver Dis. 32, 147-157 (2012).
25. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26, 6266-6273 (2008).
26. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212-2219 (2012).
27. Chen HL, Lin LH, Hu FC et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 142, 773-781 (2012).
28. Dusheiko G. Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis? Lancet 379, 2019-2021 (2012).
29. Thursz M, Njie R, Lemoine M. Hepatitis: Global eradication of hepatitis B-feasible or fallacy? Nat. Rev. Gastroenterol. Hepatol. 9, 492-494 (2012).
30. Adebamowo CA, Ajuwon A. The immunization status and level of knowledge about hepatitis B virus infection among Nigerian surgeons. West Afr. J. Med. 16, 93-96 (1997).
31. Sukriti, Pati NT, Sethi A et al. Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India. J. Gastroenterol. Hepatol. 23, 1710-1715 (2008).
32. Kondili LA, Ulqinaku D, Hajdini M et al. Hepatitis B virus infection in health care workers in Albania: a country still highly endemic for HBV infection. Infection 35, 94-97 (2007).
33. Abdelwahab S, Rewisha E, Hashem M et al. Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centre. Trans. R. Soc. Trop. Med. Hyg. 106, 98-103 (2012).
34. Olokoba AB, Salawu FK, Danburam A et al. Hepatitis B virus infection amongst pregnant women in north-eastern Nigeria - a call for action. Niger. J. Clin. Pract. 14, 10-13 (2011).
35. Wurie IM, Wurie AT, Gevao SM. Sero-prevalence of hepatitis B virus among middle to high socio-economic antenatal population in Sierra Leone. West Afr. J. Med. 24, 18-20 (2005).
36. Allain JP, Candotti D, Soldan K et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 101, 2419-2425 (2003).
37. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521-1531 (2004).
38. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45, 579-587 (2007).
39. Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381(9865), 468-4675 (2012).
40. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593-1608 (2009).
41. Lacombe K, Bottero J, Lemoine M, Boyd A, Girard PM. HIV/hepatitis B virus co infection: current challenges and new strategies. J. Antimicrob. Chemother. 65, 10-17 (2010).
42. Ford N, Calmy A. Improving first-line antiretroviral therapy in resource-limited settings. Curr. Opin. HIV AIDS 5, 38-47 (2010).
43. Stewart B, Jobarteh ML, Sarge-Njie R et al. Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, west Africa. BMC Res. Notes 4, 561 (2011).
44. Kim HN, Scott J, Cent A et al. HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. J. Viral Hepat. 18, e447-e452 (2011).
45. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61 (Suppl. 1), i36-i46 (2012).
46. Ford N, Kirby C, Singh K et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 90, 540-550 (2012).
47. Durier N, Nguyen C, White LJ. Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS ONE 7, e34548 (2012).
48. Sen AK. Development as Freedom. Oxford University Press, Oxford, UK (1999).
49. Kaplan W, Laing R. Essential Medicines for Europe and the World. Essential Drugs and Medicines Policy. WHO (2004).
50. Sampat BN. Academic patents and access to medicines in developing countries. Am. J. Public Health 99, 9-17 (2009).
51. Hoen E, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J. Int. AIDS Soc. 14, 15 (2011).
52. Rawls J. A Theory of Justice. Simon & Schuster, NY, USA (1971).
53. Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet 359, 1851-1856 (2002).
54. Piot P. No time to lose. A life in pursuit of deadly viruses. WW Norton & Company Ltd, London, UK (2012).
55. Lemoine M, Girard PM, Thursz M, Raguin G. In the shadow of HIV/AIDS: forgotten diseases in sub-Saharan Africa. Global health issues and funding agency responsibilities. J. Public Health Policy 33(4), 430-438 (2012).
56. Logie DE, Rowson M, Ndagije F. Innovations in Rwanda's health system: looking to the future. Lancet 372, 256-261 (2008).
57. Tuaillon E, Mondain AM, Meroueh F et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology 51, 752-758 (2010).
58. WHO. Hepatitis B. www.who.int/csr/disease/hepatitis/ HepatitisB- whocdscsrlyo2002-2.pdf (Accessed 11 January 2013)
59. UN Development Programme. www.hdr.undp.org/en/statistics (Accessed 12 October 2012)
60. International Agency for Research on Cancer. GLOBOCAN factsheet 2008. http://globocan.iarc.fr (Accessed 11 January 2013)
61. WHO. Prevention and control of viral hepatitis infection: framework for global action. www.who.int/csr/disease/hepatitis/GHP- framework.pdf (Accessed 2 September 2012)
62. WHO. Towards universal access. www.who.int/hiv/pub/tuapr-2009-en.pdf (Accessed 2 September 2012)
63. Health Impact Fund. www.healthimpactfund.org (Accessed 11 October 2012)
64. WHO. 63rd World Health Assembly. WHA63.18: viral hepatitis (2010). http://apps.who.int/gb/ebwha/pdf-files/ WHA63/A63-15-en.pdf (Accessed 10 November 2012)
65. L'Appel de Dakar (The Dakar Appeal). www.worldhepatitisalliance.org/es/ whdinitiatives.aspx?whd=whd&iid=136 (Accessed 11 October 2012)
66. UNAIDS World AIDS Day Report. www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2012/ gr2012/20121120-UNAIDS-Global- Report-2012-en.pdf (Accessed 11 January 2012)